Cleerly is a digital health company using artificial intelligence to transform how heart disease is diagnosed, monitored, and treated. By analyzing non-invasive coronary CT angiography (CCTA) scans, Cleerly enables earlier, more accurate detection of atherosclerosis and other signs of coronary artery disease before symptoms appear.
Developed by leading cardiologists and supported by peer-reviewed clinical research, Cleerly’s platform applies advanced AI algorithms to quantify and characterize plaque in the coronary arteries. Unlike traditional approaches that focus on symptoms or risk scores, Cleerly enables physicians to see the actual disease burden and its progression over time.
The company’s mission is to create a world without heart attacks by shifting cardiovascular care from reactive treatment to proactive prevention, using data-driven insights that help clinicians and patients take action earlier.
Features
AI-Powered CCTA Analysis: Cleerly analyzes coronary CT angiography images to detect and measure atherosclerotic plaque with precision far beyond traditional imaging interpretation.
Quantitative Plaque Measurement: The system quantifies total plaque burden, plaque types (calcified, fibrous, lipid-rich), and percent stenosis, helping physicians assess risk more accurately.
Personalized Risk Assessment: Cleerly provides clinicians with detailed reports that translate imaging data into patient-specific insights, supporting personalized treatment plans.
Longitudinal Tracking: The platform allows for monitoring plaque progression or regression over time, enabling proactive adjustments to therapies or lifestyle interventions.
Cloud-Based Delivery: Cleerly’s software is cloud-native, ensuring scalable access for hospitals, imaging centers, and cardiology practices without on-premise installation.
Clinician-Friendly Reports: The output includes intuitive, visually rich reports with key findings and recommendations that simplify clinical decision-making.
FDA-Cleared Software: Cleerly’s AI platform is FDA-cleared, providing confidence in its use in clinical settings.
Seamless Workflow Integration: Cleerly integrates into existing imaging and cardiology workflows, enhancing rather than disrupting care delivery.
How It Works
Cleerly begins with a standard coronary CT angiography (CCTA) scan performed at a radiology center or hospital. The imaging data is securely uploaded to Cleerly’s cloud platform, where it is processed using AI models trained on millions of annotated coronary artery images.
The software analyzes the scan to identify the presence, location, and characteristics of atherosclerotic plaque throughout the coronary arteries. It also evaluates the degree of stenosis (narrowing of arteries) and classifies plaque types.
Within a short time, Cleerly generates a detailed report that includes 3D visualizations, quantitative measurements, and interpretive insights. This report is sent to the ordering physician, typically a cardiologist or primary care provider, who uses the information to assess the patient’s risk and decide on further interventions.
By identifying disease before symptoms or events occur, Cleerly supports early, preventive cardiovascular care.
Use Cases
Cardiologists use Cleerly to better understand the root cause of chest pain or suspected coronary artery disease and to guide treatment based on precise plaque burden.
Primary care physicians use Cleerly’s AI reports to support earlier identification of at-risk patients, even before traditional symptoms develop.
Hospitals integrate Cleerly into cardiac imaging workflows to improve diagnostic accuracy and reduce reliance on invasive procedures like catheterization.
Preventive cardiology programs leverage Cleerly to personalize care plans for patients based on objective, quantitative coronary data.
Pharmaceutical and research institutions use Cleerly’s analysis in clinical trials to study the effects of lipid-lowering or anti-inflammatory therapies on plaque progression.
Health systems apply Cleerly for population health initiatives focused on preventing heart disease and reducing long-term costs.
Pricing
Cleerly does not publish specific pricing details on its website. Pricing is likely customized based on the size of the healthcare organization, volume of scans analyzed, integration requirements, and level of clinical support.
Cleerly’s offering is designed for enterprise use by hospitals, health systems, imaging centers, and cardiology practices.
Interested organizations can request a demo and custom pricing by contacting the Cleerly team through the official website.
Strengths
Cleerly enables early detection of coronary artery disease by focusing on the actual presence of atherosclerosis, not just symptoms or risk factors.
The platform provides detailed, quantifiable imaging insights that surpass the limitations of traditional CCTA interpretation.
FDA-cleared and validated in peer-reviewed clinical studies, Cleerly delivers clinically trusted results that physicians can rely on.
It integrates seamlessly into radiology and cardiology workflows and does not require additional hardware or on-site infrastructure.
Cleerly’s ability to track plaque over time supports more personalized and adaptive treatment approaches.
Its visual reports enhance communication between physicians and patients, helping patients understand their condition and stay engaged in their care.
Drawbacks
Cleerly is designed for use with coronary CT angiography, which requires access to imaging equipment and may not be suitable for all patients due to contrast or radiation exposure.
The platform is intended for use by healthcare providers and is not a direct-to-consumer product, limiting accessibility for individuals outside clinical environments.
Pricing and access depend on institutional adoption, so availability may vary based on healthcare provider participation.
While the technology is advanced, clinical decision-making still relies on provider expertise and cannot be fully automated.
Like any AI tool, Cleerly’s performance depends on image quality, and suboptimal scans may affect result accuracy.
Comparison with Other Tools
Cleerly competes with other cardiovascular AI platforms like HeartFlow, Artrya, and Perspectum.
HeartFlow focuses on functional assessments of coronary artery disease using FFR-CT (fractional flow reserve) technology, while Cleerly emphasizes anatomical and plaque-based analysis.
Artrya uses AI to detect vulnerable plaques and assess cardiovascular risk from imaging but is still expanding its regulatory approvals and clinical footprint.
Perspectum offers cardiac MRI tools but does not focus specifically on coronary plaque analysis.
Cleerly stands out with its deep learning-driven, plaque-centric evaluation model, FDA clearance, and proven clinical impact demonstrated through large-scale validation studies.
Customer Reviews and Testimonials
Cleerly highlights endorsements from prominent cardiologists and academic institutions involved in clinical trials and studies.
Healthcare providers using Cleerly report improved diagnostic confidence, more effective preventive strategies, and stronger engagement with patients.
Patients benefit from visual reports that help them understand their heart health more clearly, enhancing motivation to follow treatment recommendations.
Cleerly’s platform has been used in multiple high-profile research studies published in journals such as the Journal of the American College of Cardiology (JACC), affirming its clinical credibility.
Organizations interested in case studies or clinical testimonials are encouraged to request additional resources from the Cleerly team.
Conclusion
Cleerly is redefining the diagnosis and management of heart disease by applying artificial intelligence to coronary CT imaging. With its ability to quantify plaque burden, classify plaque types, and deliver actionable, personalized insights, Cleerly empowers physicians to shift from reactive treatment to proactive prevention.
For health systems, cardiology practices, and preventive care programs looking to reduce heart attacks and improve cardiovascular outcomes, Cleerly offers a groundbreaking solution that brings clarity and confidence to cardiac imaging.
